

美時公告 10 月自結合併營收新台幣 10 億 2 仟 3 百萬元、連 2 個月站穩 10 億元大關

*Lotus Reported Unaudited October Revenues of NT\$1,023 Million*

2020 年 11 月 10 日，台北

November 10<sup>th</sup>, 2020, Taipei

特殊學名藥廠美時化學製藥（以下簡稱“美時”，台灣證券交易所股票代碼：1795）公佈 2020 年 10 月自結合併營收達新台幣 1,023,290 仟元，較去年同期成長 38.4%，為今年以來第 4 個月營收站上 10 億元大關。

*Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today announced that its consolidated sales for October 2020 was NT\$1,023,290 thousand, representing a 38.4% growth over the same period last year. This is also the fourth month for Lotus to deliver monthly sales over NT\$1 billion YTD’20.*

美時表示，今年以來各項業務皆依計畫如期達成、穩定成長。其中，亞太區域在第二季整合了東南亞市場後，即積極拓展產品佈局、並首次將旗下重磅癌症用藥在菲律賓、印尼等國申請藥證；在外銷業務方面，除戒癮用藥在美國市場市佔穩定領先、癌症用藥品項亦透過全球策略合作夥伴網絡持續擴張目標市場，南投廠區更於 10 月初通過巴西國家衛生監督局(ANVISA)認證通過，為美時進軍中南美洲最大市場奠定了穩固基石、強化外銷長期競爭優勢。

*Key milestones of both Asian Business and Export Business have been delivered as scheduled and all business lines are growing steadily – the Company has been aggressively extending its oncology portfolio into ASEAN markets since the completion of ASEAN markets integration in Q2’20 and even made its first ever MA applications for its oncology products in major distribution markets, such as Philippines and Indonesia. Moreover, its outstanding GMP and quality system of its Nantou site got approved by The Brazilian National Health Surveillance Agency (“ANVISA”) in Oct’20, which paves the Company’s submissions in the largest pharma market in Latin America and further solidifies its long term competitive advantages for Export Business on top of its well-connected global partnership with industry leaders for its self-developed oncology products around the globe.*

**新聞聯繫人 Contact:**

美時製藥 投資人關係處長 樂君儀 (02)2700 5908 investor@lotuspharm.com

**Angela Luan, Investor Relations Director**

**關於美時：**

美時化學製藥股份有限公司（股票代碼：1795）成立於 1966 年，為一以台灣為基地供應全球市場之學名藥廠，高價值產品線涵蓋中樞神經系統、心血管疾病、癌症、女性保健、減肥等，並以錠劑、膠囊及軟膠囊劑型為主；美時自 2014 年成為艾威群集團的一員，現專注於快速成長的抗癌市場，並矢志透過整合台灣與韓國首屈一指的研發平台與其製造優勢嘉惠病患、員工與股東。美時的行銷與業務通路包含直營的亞洲市場及艾威群集團橫跨全球超過 30 個國家的商業網絡，此外，美時亦積極與一線藥廠就產品線策略結盟，是少數能進軍所有市場的新興藥廠。

**About Lotus**

*Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company's internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company's direct markets, relationship with Alvogen's commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.*

**聲明：**

本文件及同時發佈之相關資訊內含有預測性敘述。除針對已發生事實，所有對美時製藥(以下簡稱本公司)未來經營業務、可能發生之事件及展望（包括但不限於預測、目標、估算和營運計劃）之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性的影響，造成與實際情況有相當差異，這些因素包括但不限於價格波動、實際需求、匯率變動、市占率、市場競爭情況，法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等，及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估，本公司不負日後更新之責。